ValuEngine Downgrades Obseva (NASDAQ:OBSV) to Hold

Obseva (NASDAQ:OBSV) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a report released on Wednesday, May 8th, ValuEngine reports.

Several other research analysts also recently commented on OBSV. Wedbush set a $34.00 price target on shares of Obseva and gave the stock a “buy” rating in a research note on Friday, January 25th. HC Wainwright reissued a “buy” rating on shares of Obseva in a research note on Monday, April 29th. Zacks Investment Research downgraded shares of Obseva from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. Finally, TheStreet cut shares of Obseva from a “c-” rating to a “d+” rating in a report on Wednesday, January 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $29.14.

NASDAQ:OBSV traded down $0.04 on Wednesday, reaching $12.55. 35,799 shares of the company’s stock were exchanged, compared to its average volume of 32,575. The company has a quick ratio of 6.73, a current ratio of 6.73 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $573.47 million, a PE ratio of -6.57 and a beta of 1.16. Obseva has a 52 week low of $10.23 and a 52 week high of $20.35.

Obseva (NASDAQ:OBSV) last issued its earnings results on Thursday, May 9th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.09). The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.01 million. Analysts anticipate that Obseva will post -2.27 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. First Manhattan Co. raised its position in shares of Obseva by 38.2% in the 4th quarter. First Manhattan Co. now owns 2,117,112 shares of the company’s stock worth $26,802,000 after purchasing an additional 584,646 shares during the last quarter. Aisling Capital Management LP purchased a new position in Obseva in the 4th quarter worth about $17,551,000. Fosun International Ltd purchased a new position in Obseva in the 1st quarter worth about $2,494,000. Polar Capital LLP raised its position in Obseva by 16.7% in the 4th quarter. Polar Capital LLP now owns 175,000 shares of the company’s stock worth $2,216,000 after buying an additional 25,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Obseva by 92.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 135,547 shares of the company’s stock worth $1,734,000 after buying an additional 64,974 shares during the last quarter. 63.58% of the stock is owned by hedge funds and other institutional investors.

Obseva Company Profile

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Recommended Story: How to Use a Moving Average for Trading 

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Obseva (NASDAQ:OBSV)

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.